J&J says its Covid vaccine booster shot generated a promising immune response in early trials

0 3
A man receives a shot of Johnson & Johnson Covid-19 vaccine at a pop-up vaccination center at the beach, in South Beach, Florida, on May 9, 2021.Eva Marie Uzcategui | AFP | Getty ImagesJohnson & Johnson said Wednesday a booster shot of its Covid-19 vaccine generated a promising immune response in early-stage clinical trials – though the information provided by the company in a press release was light on some details.J&J's vaccine requires only one dose and recipients are considered fully vaccinated two weeks after receiving the shot. The company said Wednesday that J&J recipients who received a booster dose of the shot generated virus-fighting antibodies "nine-fold higher" than those seen four weeks after a single dose.Increases in antibody responses were observed in vaccine trial participants between ages 18 and 55, the company said, and in those 65 years and older who received a lower dosage of the booster shot.The results are based on two Phase 1/2 studies
Subscribe or log in to read the rest of this content.
Leave A Reply

Your email address will not be published.